DAS is a private, specialty pharmaceutical company with headquarters in California, USA and a wholly owned subsidiary in France. It is the first company, worldwide, with the sole purpose of developing medications for the treatment of alcohol and other drug addictions.
Addiction is the top healthcare problem for the U.S. and Europe.
However, the absence of such words does not mean that a statement is not forward-looking. The Company's actual results could differ materially from those discussed herein, due to risks and uncertainties regarding, among other things, the drug discovery and development process, the results of the Company's ongoing and planned clinical studies of its drug candidates, scientific and technological uncertainties regarding the Company's drug candidates, whether the Company's patent rights will provide sufficient protection against competitive products, the Company's burn rate and need for additional capital, which could substantially increase at any time, the timing of filing for regulatory approval of Naltrexone Depot, and if such approval is received, time to market thereafter and competition from other products.